fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

NASDAQ Breaks 20K Mark With Mixed Macroeconomic Reports & Fed Decision In View – $EPRX $MSTR $RKLB Rise!

By John F. Heerdink, Jr.

Inflation Data and Rate Cut Expectations

November’s economic data painted a complex picture, with the Consumer Price Index (CPI) rising to 2.7% year-over-year and core CPI holding at 3.3%, still above the Fed’s 2% target. The Producer Price Index (PPI) showed unexpected acceleration, climbing to 3.0% year-over-year from 2.6% in October. Despite these inflationary pressures, labor market indicators softened, with initial jobless claims increasing to 242,000 and continuing claims rising to 1.886 million. This mixed economic landscape has paradoxically bolstered expectations for a rate cut, with the CME FedWatch tool now indicating a 95.3% probability of a 25 basis point reduction at the upcoming FOMC meeting Dec. 17-18, up from 86.0% a week prior.

Nasdaq Hits 20k Milestone

The Nasdaq Composite reached a milestone this week, closing above 20,000 for the first time, while other major indices experienced declines amid mixed economic data and shifting expectations for Federal Reserve policy. The tech-heavy index’s historic achievement was accompanied by a mixed performance across other major U.S. stock benchmarks. Surpassing the 20,000 mark for the first time, the Nasdaq Composite’s historic achievement underscores the continued strength of the technology sector in the face of broader market challenges. This milestone comes amid a backdrop of mixed economic signals, with the index’s .3% weekly gain standing in stark contrast to the performance of its peers. The divergence highlights the tech-centric nature of recent market rallies, as investors continue to favor high-growth technology stocks despite ongoing concerns about valuations and potential market consolidation. While the Nasdaq Composite edged up .3%, the S&P 500 and Dow Jones Industrial Average experienced declines of 0.6% and 1.8% respectively. The Russell 2000, representing smaller companies, underperformed significantly with a 2.6% loss. Market sentiment was influenced by concerns over valuations and short-term overbought conditions, prompting some investors to engage in profit-taking as Treasury yields climbed. The 10-year yield surged 25 basis points to 4.40%, while the 2-year yield increased by 14 basis points to 4.24%.

Corporate Earnings Highlights

Oracle’s fiscal Q2 earnings report disappointed investors, leading to a 9.6% decline in its stock price. The company missed the consensus EPS estimate compiled by FactSet and issued lower-than-expected guidance for fiscal Q3. Similarly, Adobe’s FY25 guidance fell short of investor expectations. In contrast, Broadcom emerged as a standout performer, with its shares surging 25.2% following strong results and optimistic guidance. These divergent outcomes highlight the varied landscape of corporate performance in the tech sector, with some companies facing challenges while others capitalize on market opportunities.

VP Watchlist Updates

Now let’s check out how these nuggets progressed below!


MicroStrategy (MSTR, up +175.41% over the last 6-months) will reportedly be added to the Nasdaq-100 Index.


Eupraxia Pharmaceuticals (EPRX, $3.4431, +10.36% over the last 5-days and +24.75% over the last 6-months) is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. The Company strives to provide improved patient benefit and has developed technology designed to deliver targeted, long-lasting activity with fewer side effects. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tuneable pharmacokinetic (PK) profiles. This investigational technology can be engineered for use with multiple active pharmaceutical ingredients and delivery methods.

On Nov. 20, Eupraxia unveiled new pharmacokinetic (“PK”) data from its Phase 2a Eosinophilic Esophagitis (“EoE”) program. Management believes these data underscore the unique capabilities of Eupraxia’s proprietary DiffuSphere™ platform technology, which aims to provide precise, localized, safe, and effective long-lasting drug delivery. Most conventional drugs release in a pattern characterized by steep peaks and rapid declines in drug concentration, where peaks often lead to negative side effects, and troughs result in reduced efficacy. In contrast, DiffuSphere™ is a unique microsphere that is designed to enable precise drug release into target tissues with a flat, stable, and long-lasting profile, minimizing potential adverse events associated with high-dose systemic delivery. What sets DiffuSphere™ apart is its composition: a pure drug crystal encased in a microns-thick polymer shell. Eupraxia’s proprietary technology uses this polymer to precisely control a drug’s release, ensuring high drug concentrations in the target tissues while minimizing exposure to the rest of the body. This innovative approach has been observed in Eupraxia’s clinical programs, demonstrating precision, tolerability, and extended duration of delivering fluticasone propionate (“FP”) directly to the intended tissues for EoE and knee osteoarthritis (“OA”) patients.

On Nov. 15., Eupraxia Pharmaceuticals Inc.’s Chief Executive Officer, James Helliwell. M, delivered a presentation titled “Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed” and was available for a Q&A session at the end of the presentation. The video can be viewed below: 

On Nov. 12, Eupraxia announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (“EoE”). EoE is an inflammatory-mediated disease in which white blood cells migrate into and become trapped in the esophagus, creating pain and difficulty with swallowing food. According to market research from Clearview Healthcare Partners, EoE affects more than 450,000 people in the United States and has been identified by the American Gastroenterological Association as rapidly increasing in both incidence and prevalence. Impacts from both symptoms and interventions frequently lead to mental health issues, compounding the disease burden of EoE for both the healthcare system and the individual. Eupraxia highlighted the following:

  • One of three patients in Cohort 5 achieved complete histological remission at 12 weeks.
  • Consistent improvement in patient-reported outcomes with six of six evaluable patients in the fourth and fifth cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeks.
  • At 24 weeks, the fourth cohort experienced the largest average reduction in SDI scores of all cohorts to date.
  • The fifth cohort continued to show improved patient outcomes with the greatest percentage change in histology (EoEHSS2) scores of any cohort to date.
  • Both the mean reduction in Peak Eosinophil Counts (PEC3)at four biopsy sites and the percent change in histology (EoEHSS2) scores showed a clear dose response across Cohorts 3 to 5, with Cohort 5 showing the greatest response. No serious adverse events reported in any of the five cohorts to date.
  • Cohort 6 is now fully enrolled and dosed, with 12-week data anticipated in Q1 2025.

On Nov. 7, Eupraxia announced its financial results for the third quarter of 2024. they highlighted the following:

  • On September 11, 2024, the Company announced additional positive clinical data from its RESOLVE Phase 1b/2a trial which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (“EoE”).
  • Presented RESOLVE clinical trial data at the Controlled Release Society 2024 Annual Meeting and Expo in Italy in July, and at the 20th International Symposium on Digestive Endoscopy World Congress for Esophageal Diseases in Scotland in September.
  • Subsequent to quarter end, on October 2, 2024, the Company announced the appointment of Dr. Amanda Malone as the Chief Operating and Scientific Officer of the Company. In addition, the Company announced the appointment of Dr. Rahul Sarugaser as Executive Vice President of Corporate Development.
  • Subsequent to quarter end, on October 15, 2024, the Company announced that Phase 2b data from its SPRINGBOARD trial evaluating EP-104IAR for the treatment of knee osteoarthritis was published in leading peer reviewed medical journal The Lancet Rheumatology.
  • Subsequent to quarter end, on October 31, 2024, the Company announced the closing of a non-brokered private placement of C$44.5 million, the appointment of Mr. Joseph Freedman to its Board of Directors and the termination of its new C$12 million convertible debt facility.

On Oct. 31 Eupraxia announced that it has completed a non-brokered private placement of 8,905,638 Series 1 Preferred shares of the Company (the “Preferred Shares”), at a price of C$5.00 per Preferred Share for aggregate gross proceeds of C$44,528,190, by way of a non-brokered private placement (the “Private Placement”). The Company intends to use the net proceeds from the Private Placement towards the funding of clinical trials for EP104GI, initiating research programs for new candidates and general corporate and working capital purposes of the Company and its affiliates. In connection with the closing of the Private Placement, the Company has appointed Mr. Joseph Freedman to its board of directors. Mr. Freedman is a private equity investor and corporate director with more than 25 years industry experience including, most recently, 18 years at Brookfield Asset Management, one of the world’s leading private equity and alternative asset management firms. Over his career at Brookfield, Mr. Freedman has held a number of positions, including Vice Chair of Private Equity, General Counsel and the Partner responsible for M&A transaction execution, fund formation and fund operations. Prior to joining Brookfield, he was a lawyer in the corporate finance group at a Toronto law firm, specializing in private equity transactions and public company mergers and acquisitions. Now retired from Brookfield, Mr. Freedman is a director of several private and public companies and non-profit organizations including the Centre for Aging and Brain Health Innovation (co-chair), Bridgemarq Real Estate Services (TSX:BRE) and Total Containment Inc. Mr. Freedman holds a joint MBA/LL.B from the Schulich School of Business at York University and Osgoode Hall Law School in Toronto.


 

The global diabetes care market, valued at $18.9 billion in 2023, is projected to reach $35.8 billion by 2028, with the insulin pump segment expected to grow from $5.26 billion to $21.65 billion by 2032. As reported by Fortune Business Insights, this rapid growth is driven by increasing diabetes prevalence and technological advancements in insulin delivery devices.

Modular Medical, Inc. (NASDAQ: MODD, $1.59, -5.92% over the last 5-days), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Their mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond “superusers” and providing “diabetes care for the rest of us.” Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.

On November 21, Modular announced that it has priced an underwritten public offering (the “offering”) of 5,450,573 shares of its common stock. The offering was led by existing institutional investors, including Manchester Explorer, L.P., which is the largest shareholder of the Company and is managed by Jeb Besser, Modular Medical’s Chief Executive Officer. The shares of common stock are being sold at a price to the public of $1.50 per share of common stock, less underwriting discounts and commissions. The gross proceeds to the Company from the offering are expected to be approximately $8.2 million, before deducting underwriting discounts, commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund operations and for working capital and general corporate purposes, including capital expenditures. The offering is expected to close on or about November 25, 2024, subject to the satisfaction of customary closing conditions.

On November 11, Modular Medical, Inc.’s Chief Executive Officer, Jeb Besser delivered a presentation titled “Tailoring GLP-1 Weight Loss Treatments: Innovative Approaches To Personalized Dosing.” He was also available for a 5-10 minute Q&A session at the end of the presentation. 


On Nov. 7, Modular Medical announced successful results from its pre-clinical GLP-1 proof of concept study.  They highlighted the following: Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery, Observed weight loss was 17% at 28 days, a 25% improvement over GLP-1 delivered as basal alone, & Findings suggest that pump delivery may be a viable approach to achieve GLP-1 weight and blood glucose benefits that are comparable with current treatment standards, either as initial treatment or for maintenance, while bringing personalized dosing flexibility. “With these encouraging results, we are now planning to take this concept of a synergistic basal-bolus GLP-1 combination into a human trial using our MODD1 device. We are considering both existing fast acting GLP-1s and other peptides for this trial, as we see this as a platform technology that could be used for more personalized titration for both non-responder or non-adherent patients experiencing GI and other issues with long acting GLP-1s, as well as for other specialty applications in metabolic therapies. This type of application is well suited for our MODD1 pump, given its quick training time, simple interface, high accuracy at low flow rates, reusable low-cost electronics, and a prefill-capable 3mL reservoir,” stated Jeb Besser, CEO of Modular Medical.

In October, Modular’s CEO was interviewed by Carole Sullivan on the Today In Nashville program affiliated with Channel 4 WSMV. The segment is called “New Tools for Treating Diabetes by Modular Medical.” You may watch the video now at this link.

On September 18, Modular Medical announced the issuance of U.S. Divisional Patent Application No. 17/968,599. “The issuance of this patent and the associated claims represent a major step in our efforts to protect the intellectual property in the MODD1 pump platform,” stated Jeb Besser, CEO of Modular Medical. “Some of the key features of our novel, low-cost and accurate insulin delivery technology are now protected by this important issued U.S. patent, which we believe represents a significant new barrier to entry. Our eight families of patents around our pump are an important part of our strategic value and market positioning, and we look forward to announcing further issuances on our portfolio in the future.”

On Wednesday, September 4, Modular announced it has received U. S. Food and Drug Administration (“FDA”) clearance to market and sell its MODD1 pump in the United States. With its commercial manufacturing infrastructure substantially established, the Company anticipates the MODD1 should be available for sale in early 2025.

 

James (Jeb) Besser, CEO of Modular Medical (NASDAQ: MODD)

“For too long, the benefits of superior glycemic control achieved by insulin pumps have, due to cost and complexity, been restricted to only the most sophisticated, motivated and well-insured users. The goal of Modular Medical has always been to change this by making diabetes technology accessible and affordable to underserved communities. We seek to make the experience of going ‘on a pump’ simpler and less intimidating and to widen the base beyond the current pump users,” said Jeb Besser, CEO of Modular Medical.


Shares of Indaptus Therapeutics, Inc. (Nasdaq: INDP) closed at $1.0, -3.85% over the last 5-days.  Indaptus is a company with the ability to harness both the body’s innate and adaptive immune responses, believes that they are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (Nod)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The products are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy products represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts.

On Nov. 22, Indaptus announced that it has entered into securities purchase agreements with investors, including an officer of Indaptus, for the issuance and sale of an aggregate of 1,817,017 of its shares of common stock. In a concurrent private placement, Indaptus has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 1,817,017 of its shares of common stock. The combined effective purchase price for each share of common stock and associated warrants is $1.175. The warrants will have an exercise price of $1.05 per share, will be immediately exercisable upon issuance and have a term of five years from the date of issuance. The closing of the offering is expected to take place on or about November 25, 2024, subject to the satisfaction of customary closing conditions. Paulson Investment Company, LLC is acting as the exclusive placement agent in connection with the offering. The gross proceeds to Indaptus from the offering are expected to be approximately $2.135 million, before deducting the placement agent’s fees and other offering expenses payable by Indaptus. Indaptus intends to use the net proceeds from the offering to fund its research and development activities and for working capital and general corporate purposes.

On Nov. 11, Indaptus announced that Dr. Michael Newman, Founder and Chief Scientific Officer, has published his groundbreaking research in the peer-reviewed journal, Frontiers in Immunology. The article, titled “Invention and Characterization of a Systemically Administered, Attenuated and Killed Bacteria-Based Multiple Immune Receptor Agonist for Antitumor Immunotherapy,” presents the Company’s innovative approach to activating both the innate and adaptive sides of the immune system to treat cancer. The paper is being published as part of a Research Topic on The Vital Role of Innate Immunity in Cancer Immunotherapy. This publication describes the invention and pre-clinical characterization of the Decoy platform, including Decoy20, a novel clinical stage immunotherapy candidate. Decoy20 leverages attenuated, killed and stabilized bacteria to activate multiple immune pathways with a weekly pulse, aimed at creating a comprehensive immune response against tumors. By priming or activating both the innate and adaptive immune systems, Decoy20 has demonstrated the potential to enhance immune responses to effectively fight various types of cancer, including colorectal, pancreatic, hepatocellular cancers and lymphomas. Dr. Newman’s study highlights Decoy20’s potential advantages over traditional treatments, such as chemotherapy, as well as its potential to significantly enhance the efficacy of current, single-target immunotherapy, because it triggers a broad yet controlled activation of the immune system while reducing toxicity often seen with other cancer immunotherapies. Dr. Newman commented, “It is incredibly rewarding to have our work recognized in such a prestigious publication. I am honored to share years of scientific research with the broader scientific community, contributing a deeper understanding of our ‘pulse-prime’ approach to enhancing both innate and adaptive immune activation. We believe this methodology, represents a significant step toward more effective cancer immunotherapy.”

Key Highlights from the Research:

  • Multi-Pathway Immune Activation: Unlike traditional immunotherapies that focus on a single immune pathway, Decoy20 engages multiple immune receptors, including Toll-like, NOD-like, and STING receptors, to initiate a broader and more durable immune response.

  • Encouraging Preclinical Data: Decoy20 has produced efficacy in preclinical studies across a variety of tumor types and in combination with four different classes of existing drugs, demonstrating both innate and adaptive immune activation that led to tumor regression and immunological memory.

  • Reduced Toxicity Profile: By using a rapidly cleared, bacteria-based delivery package and significantly lowering but leaving a small amount of immune activating LPS-endotoxin activity, Decoy20 is designed to produce a broad, but transient or pulsed activation of innate and adaptive immune pathways, minimizing toxicity and enabling safe systemic administration – a longstanding challenge with novel cancer immunotherapies.

On Nov. 7, Indaptus Therapeutics announced compelling safety, pharmacokinetics, and biomarker data on its lead compound, Decoy20, at the Society for Immunotherapy of Cancer (SITC) 2024 annual meeting. The data derive from two cohorts (13 patients) of Decoy20 single administration and one cohort (6 patients) of Decoy20 weekly administration in the Company’s ongoing Phase 1 clinical trial. The SITC conference is being held November 6-10, 2024 in Houston, TX. The data presented demonstrated that Decoy20 administered intravenously once weekly mainly showed side effects that were classified as mild or moderate and transient in duration. Further, pharmacokinetic analysis confirmed that Decoy20 quickly disappeared from the bloodstream after administration, supporting the Company’s “pulse” approach. One patient in the trial who has squamous cell carcinoma of the head and neck (SCCHN) with high levels of PD-L1, which is a protein that is associated with tumor response to certain immunotherapies, had “stable disease” — meaning the cancer had not progressed or worsened — at the time of their first imaging scan. “We continue to be encouraged by the safety profile of Decoy20 when administered weekly,” said Dr. Roger Waltzman, Chief Medical Officer. “In addition, we see a broad innate and adaptive immune response. Based upon pre-clinical data, we expect Decoy20 combined with a PD-1 inhibitor to work together effectively to control tumors.”

On October 22, Indaptus announced a clinical supply agreement with BeiGene (BGNE). Building on Indaptus’ preclinical observation that Decoy20, when combined with a PD-1 inhibitor, induced complete cancer regressions and immunological memory in animal models, Indaptus plans to advance human clinical evaluation of the combination of BeiGene’s anti-PD-1 antibody, tislelizumab, with Indaptus’ Decoy20, a novel treatment designed to induce a broad immune response to fight cancer. Indaptus’ Decoy20 is being studied for its potential to treat a variety of cancers, including liver, colon, and pancreatic. PD-1 inhibitors are considered key agents in modern immunotherapy and have produced impressive response rates in some patients. In preclinical studies, Decoy20, when used in combination with a PD-1 inhibitor and an oral non-steroidal anti-inflammatory agent, demonstrated tumor eradication rates of 80-100%. Indaptus hopes to find a treatment combination that similarly improves outcomes in humans.

“PD-1 inhibitors have proven to be meaningful in treating multiple types of cancer. We are optimistic that we can improve outcomes by broadly and safely stimulating the immune system in a way that could enhance overall effectiveness of currently approved cancer treatments,” said Jeffrey Meckler, CEO of Indaptus Therapeutics. “This agreement with BeiGene marks a significant step forward in the search for curative cancer treatments for some of the most challenging cancers. Additionally, we view this as a significant milestone for Indaptus.”

As part of the agreement, BeiGene will provide Indaptus with access to its PD-1 inhibitor as well as technical expertise in order to accelerate the first clinical trial combining the two investigational drugs. Decoy20 utilizes Indaptus’ unique “Pulse-Prime” approach, which induces a strong and broad boost to the immune system but clears rapidly with only transient and tolerable side effects.

“Decoy20’s ability to synergize with a variety of approved therapeutic modalities, including checkpoint therapy, makes it a promising partner for several novel combination approaches,” said Dr. Michael Newman, Founder and Chief Scientific Officer at Indaptus. “This trial could reshape the checkpoint therapy landscape, as it will be the first time a short but broadly acting agent such as Decoy20, utilizing our innovative Pulse-Prime approach, will be tested in combination with a PD-1 inhibitor.”

On October 15, Indaptus Therapeutics, Inc. (Nasdaq: INDP) provided an update regarding key clinical advancements in its Phase 1 trial of lead drug candidate Decoy20. The Safety Review Committee examined weekly administration data at the lower Decoy20 dose and cleared unrestricted enrollment of patients at this dose. The safety profile observed to date remains aligned with Decoy20’s expected mechanism of action. The most clinically relevant treatment-related adverse events include Grade 2 Infusion Related Reaction and Grade 2 Hypotension, both of transient duration.  Jeffrey Meckler, Chief Executive Officer, added, “We continue to gather robust data on Decoy20, which remains consistent with our expectations from preclinical studies. We believe the continuation of this trial, and the eventual initiation of combination therapy studies presents an important opportunity to have a potentially significant impact on cancer immunotherapy. We look forward to sharing these results in the coming months.”


Lantern (LTRN) closed at $3.445, -13.44% over the last 5-days.  Lantern is an Artificial Intelligence (AI) firm that is transforming the cost, pace, and timeline of oncology drug discovery and development and specifically is developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs.

On December 9, Lantern announced that the first patient has been enrolled and dosed in Taiwan for its Phase 2 HARMONIC™ clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with tyrosine kinase inhibitors (TKIs). The enrollment of the first patient in Taiwan extends the recent expansion of the HARMONIC™ trial into Asia, where there is a notably higher prevalence of never-smoker NSCLC patients compared to Western populations. Taiwan represents a particularly important region for the trial, as more than half of all new lung cancer diagnoses in Taiwan occur in people who are classified as never-smokers. Never-smokers in the context of lung cancer have been commonly defined, by the CDC and other health agencies, as people who have smoked less than 100 cigarettes in their lifetime. The scientific and clinical community is increasingly recognizing that lung cancers in nonsmokers and never-smokers represent a distinct disease entity with unique clinical, genomic, pathological, and biological characteristics. Lantern believes that this has particular importance for the Harmonic™ trial, as it underscores the need of targeted, precision therapy approaches for this unique patient population. Lung cancer in never-smokers constitutes one of the top 10 causes of cancer-related deaths globally, making it a crucial focus for therapeutic innovation.

On December 3, Lantern announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Triple Negative Breast Cancer (TNBC). This marks the second Fast Track Designation received for LP-184 in 2024, following its designation for Glioblastoma in October.

On November 26, Lantern and its wholly-owned subsidiary Starlight Therapeutics, focused exclusively on CNS and brain cancers, announced the presentation of new preclinical data and Phase 1b trial design for LP-184 (to be developed as STAR-001 for CNS indications) in glioblastoma at the Society for Neuro-Oncology (SNO) 2024 Annual Meeting in Houston, Texas. The poster presentation highlighted LP-184’s unique mechanism of action, brain penetrance properties, and potential enhanced therapeutic effect when combined with spironolactone in glioblastoma multiforme (GBM). LP-184 is currently under investigation in a Phase 1a dose-escalation safety study (NCT05933265) in adult patients with advanced solid tumors including GBM. “The data and trial design presented at SNO2024 further validate and progress LP-184’s potential as a promising new treatment option for glioblastoma patients,” said Panna Sharma, President and CEO of Lantern Pharma. “Through our subsidiary Starlight Therapeutics, we are positioned to advance LP-184 as STAR-001 specifically for brain cancers and CNS indications, where treatment options are limited and often ineffective. The combination with spironolactone represents an innovative approach, which has been developed with the aid of our AI platform RADR®, to potentially enhance therapeutic response in this devastating disease.”

On Nov. 19, Lantern announced that the first patient has been dosed – as part of the expansion cohort – in Japan for its Phase 2 HARMONIC™ clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with tyrosine kinase inhibitors (TKIs). The dosing of the first patient in Japan marks a significant expansion of the HARMONIC™ trial into Asia, where there is a notably higher prevalence of never-smoker NSCLC patients compared to Western populations. The trial is being conducted at five sites across Japan, including the National Cancer Center Japan under the leadership of Dr. Yasushi Goto, a renowned physician-researcher focused on lung cancer.

After the close Nov. 7, Lantern reported its Q4, 2024 financial results and business updates highlighting the following:

  • Lantern is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials, while evaluating additional ADC-based preclinical molecules for development.
  • Preliminary patient data and clinical readouts for the Phase 2 LP-300 Harmonic™ Trial showed an 86% clinical benefit rate in the initial 7 patient lead-in cohort, and additional patients continue to be enrolled in the US.
  • The Harmonic™ Trial has been expanded to both Japan and Taiwan with an expected 10 sites in East Asia; 5 in each country where the population of never-smokers is 33 to 35 percent of new cases in NSCLC.
  • Phase 1 clinical trials for both synthetic lethal drug candidates, LP-184 and LP-284, continue to advance with no dose-limiting toxicities observed in any of the patient cohorts enrolled and over 50 patients dosed to-date across both trials.
  • LP-184, which will be developed as STAR-001 for CNS and other neuro-oncology indications, received Fast Track Designation in Glioblastoma (GBM) from the FDA.
  • Patients with recurrent GBM have been enrolled in the LP-184 Phase 1a trial at 2 academic centers, including Johns Hopkins, and 1 community site; the data will help guide later stage clinical development planned to be sponsored by Starlight Therapeutics during early 2025.
  • Biomarker analysis for PTGR1 expression using qPCR for the first 7 cohorts of patients enrolled in the Phase 1a LP-184 clinical trial has begun, and will help guide the advancement of PTGR1 as a key RNA biomarker that can guide patient response prediction.
  • Three U.S. FDA Rare Pediatric Disease Designations were granted to LP-184 in three ultra rare children’s cancers.
  • Three scientific publications in Q3 including: a peer-reviewed paper regarding the unique AI-powered module for ADC development as part of the RADR® platform; and findings presented at conferences regarding the ongoing development of Lantern’s synthetically-lethal drug candidates at the Immuno-Oncology Summit for LP-184 and The Society of Hematologic Oncology for LP-284.
  • Approximately $28.1 million in cash, cash equivalents, and marketable securities as of September 30, 2024.

On October 28. Lantern’s CEO Pana Sharma discussed in detail how big data and AI are being leveraged to advance the development of multiple indications for drug-candidates LP-184 and LP-284 during the Tribe Public CEO Presentation and Q&A Webinar Event titled  “Leveraging Artificial Intelligence to Develop Therapies for Brain and Childhood Cancers.”

Click here to watch the event video now

On October 15, Lantern Pharma announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Glioblastoma. LP-184 is currently in a Phase 1A clinical trial designed to evaluate the safety and tolerability of the synthetically lethal investigational drug candidate in a broad range of solid tumors, including Glioblastoma (GBM). LP-184 was optimized and advanced in part with Lantern’s AI platform, RADR®, to aid in the validation of mechanisms that could be exploited in the clinical setting to eradicate challenging cancers, and uncover insights in targeted patient populations. RADR® is Lantern’s AI platform for cancer therapy discovery, development and rescue with over 100 billion data points and aiding in the development of both Lantern’s portfolio and development initiatives with Lantern’s collaborators. Fast Track Designation is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need. Fast Track Designation for LP-184 (STAR-001) recognizes Glioblastoma (GBM) as a serious condition impacting more than 13,000 U.S. adults each year and approximately 300,000 globally. A phase 1b/2a clinical trial for recurrent GBM is targeted to start in late 2024/early 2025. LP-184, which will be developed as STAR-001 for CNS and other neuro-oncology indications by Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma, has the potential to be the first new drug for treating GBM in more than 20 years.

On September 23, Lantern announced that the company has been granted three rare pediatric disease designations (RPDD) by the FDA. Lantern was granted these rare pediatric disease designations in: malignant rhabdoid tumors (MRT), rhabdomyosarcoma (RMS), and hepatoblastoma. Rare pediatric diseases are defined by the FDA as serious or life-threatening conditions primarily affecting children under 18, with fewer than 200,000 cases in the U.S. A key benefit of obtaining a RPDD is the potential to receive a priority review voucher following FDA approval of a product with RPDD if the marketing application submitted for the product satisfies certain conditions, including approval prior to September 30, 2026 unless changed by legislation. These vouchers, often called “golden tickets,” can significantly expedite the review process for future NDAs or biologic license applications, reducing the standard review time from about ten months to six. Sponsors can either use these vouchers themselves or sell them to other companies. These vouchers, in the recent past, have commanded sales prices of approximately $100 million USD.

 

Shares of ADT Inc. (ADT), a leading provider of monitored security and automation solutions for residential and small business customers in the United States and Canada, closed at $7.20, -4.38% over the last 5-days after recently reporting results for the third quarter of 2024 that beat the street’s estimates and highlighting the following: Continued strong financial results, cash generation, and leverage reduction, Revenue up 5% versus prior year period, GAAP income from continuing operations up 7%; Adjusted EBITDA up 6%, Record-high recurring monthly revenue; solid customer retention, & On track to achieve full year 2024 guidance metrics.

Rocket Lab USA, Inc   (Nasdaq: RKLB, $24.42, up +395.33% over the last year), a leading launch provider and space systems company, announced (Dec. 9) that it successfully launched a suborbital mission in November to test hypersonic technology for the Department of Defense. This mission provided hypersonic test launch capabilities under the Multi-Service Advanced Capability Hypersonics Test Bed (MACH-TB) project, which aims to increase hypersonic flight testing for the United States in support of technology maturation. The project was awarded by Naval Surface Warfare Center (NSWC) Crane through the Strategic and Spectrum Missions Advanced Resilient Trusted Systems (S2MARTS) Other Transaction Authority (OTA) vehicle on behalf of the U.S. Department of Defense Test Resource Management Center (TRMC). George Rumford, Director of the TRMC, states: “Leveraging commercial launch services allows our Nation to affordably test components early and frequently, accelerating hypersonic development.”

 

 

QUOTE OF WEEK


“In three words I can sum up everything I’ve learned about life: it goes on.” –  Robert Frost

Investing & Inspiration

  1. “In three words I can sum up everything I’ve learned about life: it goes on.” –  Robert Frost
  2. “The most worth-while thing is to try to put happiness into the lives of others.” – Robert Baden-Powell
  3. “A good beginning makes a good end.” – Louis L’Amour
  4. “Humanity is acquiring all the right technology for all the wrong reasons.” – R. Buckminster Fuller
  5. “There is a certain enthusiasm in liberty, that makes human nature rise above itself, in acts of bravery and heroism.” – Alexander Hamilton
  6. “You don’t take a photograph, you make it.” – Ansel Adams
  7. “The less we deserve good fortune, the more we hope for it.” – Lucius Annaeus Seneca
  8. “Art is the right hand of Nature. The latter has only given us being, the former has made us men.” – Friedrich Schiller
  9. “To begin, begin.” –  William Wordsworth
  10. “Nature does not hurry, yet everything is accomplished.” – Lao Tzu
  11. “The end of labor is to gain leisure.” – Aristotle
  12. “People are not disturbed by things, but by the view they take of them.” – Epictetus
  13. “Have patience. All things are difficult before they become easy.” – Saadi
  14. “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
  15. “The traveler sees what he sees, the tourist sees what he has come to see.” – Gilbert K. Chesterton
  16. “The only true wisdom is in knowing you know nothing.” – Socrates
  17. “Courage is knowing what not to fear.”– Plato
  18. “The home is the chief school of human virtues.” – William Ellery Channing
  19. “Be brave. Take risks. Nothing can substitute experience.” – Paulo Coelho
  20. “There are no shortcuts in evolution.” – Louis D. Brandeis
  21. “A friend may well be reckoned the masterpiece of nature.” –  Ralph Waldo Emerson
  22. “Nature uses as little as possible of anything.” – Johannes Kepler
  23. “Every new beginning comes from some other beginning’s end.” – Seneca
  24. “Nothing ever becomes real till it is experienced.” – John Keats
  25. “Nobody who ever gave his best regretted it.” – George Halas
  26. “Honest disagreement is often a good sign of progress.” – Mahatma Gandhi
  27. “A leader is one who knows the way, goes the way, and shows the way.” – John C. Maxwell
  28. “They always say time changes things, but you actually have to change them yourself.” – Andy Warhol
  29. “The secret of happiness is something to do.” – John Burroughs
  30. “The world of reality has its limits; the world of imagination is boundless.”
  31. “You begin with the possibilities of the material.” – Robert Rauschenberg
  32. “The only Zen you can find on the tops of mountains is the Zen you bring up there.” – Robert M. Pirsig
  33. “Leadership is the capacity to translate vision into reality.” – Warren Bennis
  34. “A man should always consider how much he has more than he wants.” – Joseph Addison
  35. “Happiness is good health and a bad memory.” –  Ingrid Bergman
  36. “We pass through this world but once.” – Stephen Jay Gould
  37. “Christmas waves a magic wand over this world, and behold, everything is softer and more beautiful.” – Norman Vincent Peale
  38. “Nothing can have value without being an object of utility.” – Karl Marx
  39. “Always turn a negative situation into a positive situation.” – Michael Jordan
  40. “Courage is found in unlikely places.” – J. R. R. Tolkien
  41. “One that would have the fruit must climb the tree.” – Thomas Fuller
  42. “Someone is sitting in the shade today because someone planted a tree a long time ago.” – Warren Buffett
  43. “We relish news of our heroes, forgetting that we are extraordinary to somebody too.” – Helen Hayes
  44. “A life spent making mistakes is not only more honorable, but more useful than a life spent doing nothing.” – George Bernard Shaw
  45. “Everything in the world may be endured except continual prosperity.”  – Johann Wolfgang von Goethe
  46. “Nine-tenths of wisdom is being wise in time.” – Theodore Roosevelt
  47. “Time is money.” – Benjamin Franklin
  48. “Change before you have to.” – Jack Welch
  49. “Our deeds determine us, as much as we determine our deeds.” – George Eliot
  50. “The Universe is under no obligation to make sense to you.” – Neil deGrasse Tyson
  51. “Care and diligence bring luck.” – Thomas Fuller
  52. “Nobody made a greater mistake than he who did nothing because he could do only a little.” – Edmund Burke
  53. “A man who is a master of patience is master of everything else.” – George Savile
  54. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  55. “Endurance is nobler than strength, and patience than beauty.” – John Ruskin
  56. “Act as if what you do makes a difference. It does.” – William James
  57. “Let us be grateful to people who make us happy, they are the charming gardeners who make our souls blossom.” –  Marcel Proust
  58. “Strength and growth come only through continuous effort and struggle.” – Napoleon Hill
  59. “Science may never come up with a better office communication system than the coffee break.” – Earl Wilson
  60. “If everyone is moving forward together, then success takes care of itself.” – Henry Ford
  61. “Hope is like the sun, which, as we journey toward it, casts the shadow of our burden behind us.”– Samuel Smiles
  62. “Patriotism is supporting your country all the time, and your government when it deserves it.” – Mark Twain
  63. “What would life be if we had no courage to attempt anything?” – Vincent Van Gogh
  64. “The biggest risk is not taking any risk… In a world that is changing really quickly, the only strategy that is guaranteed to fail is not taking risks.” – Mark Zuckerberg
  65. “Our lives improve only when we take chances – and the first and most difficult risk we can take is to be honest with ourselves.” – Walter Anderson
  66. “Action is the foundational key to all success.” – Pablo Picasso
  67. “Success is never final, failure is never fatal. It’s courage that counts.” – John Wooden
  68. “Innovation distinguishes between a leader and a follower.” – Steve Jobs
  69. “All the art of living lies in a fine mingling of letting go and holding on.” – Havelock Ellis
  70. “The size of your success is measured by the strength of your desire; the size of your dream; and how you handle disappointment along the way.” – Robert Kiyosaki
  71. “O, wind, if winter comes, can spring be far behind?” – Percy Bysshe Shelley
  72. “Patience is a virtue, and I’m learning patience. It’s a tough lesson.” – Elon Musk
  73. “Be true to your work, your word, and your friend.” – John Boyle O’Reilly
  74. “Believe in yourself! Have faith in your abilities! Without a humble but reasonable confidence in your own powers you cannot be successful or happy.” – Norman Vincent Peale
  75. “Surprise is the greatest gift which life can grant us.” – Boris Pasternak
  76. “Logic will get you from A to B. Imagination will take you everywhere.” – Albert Einstein
  77. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  78. “Do exactly what you would do if you felt most secure.” – Meister Eckhart
  79. “Life lived for tomorrow will always be just a day away from being realized.” – Leo Buscaglia
  80. “Wisdom is oftentimes nearer when we stoop than when we soar.” – Wordsworth
  81. “Take chances, make mistakes. That’s how you grow. Pain nourishes your courage. You have to fail in order to practice being brave.” – Mary Tyler Moore
  82. “A single twig breaks, but the bundle of twigs is strong.” – Tecumseh
  83. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  84. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  85. “The limits of the possible can only be defined by going beyond them into the impossible.” – Arthur C. Clarke
  86. “Be faithful in small things because it is in them that your strength lies.” – Mother Teresa
  87. “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
  88. “By three methods we may learn wisdom: First, by reflection, which is noblest; Second, by imitation, which is easiest; and third by experience, which is the bitterest.” – Confucius
  89. “No man was ever wise by chance.” – Lucius Annaeus Seneca
  90. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  91. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare
  92. “It does not matter how slowly you go as long as you do not stop.” – Confucius

  93. “I want to put a ding in the universe.” – Steve Jobs

  94. “Research is creating new knowledge.” – Neil Armstrong

  95. “The reward for work well done is the opportunity to do more.” – Jonas Salk
  96. “Man is a creative retrospection of nature upon itself.” – Karl Wilhelm Friedrich Schlegel
  97. “There’s something about taking a plow and breaking new ground. It gives you energy.” – Ken Kesey
  98. “Success seems to be largely a matter of hanging on after others have let go.” – William Feather

  99. “The essential conditions of everything you do must be choice, love, passion.” – Nadia Boulanger
  100. “More business is lost every year through neglect than through any other cause.” – Rose Kennedy

  101. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes

  102. “A person who won’t read has no advantage over one who can’t read.” – Mark Twain
  103. “The best way out is always through.” – Robert Frost

  104. “Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.” – Francis of Assisi
  105. “Without labor nothing prospers.” – Sophocles

  106. “Intellectuals solve problems, geniuses prevent them.” – Albert Einstein
  107. “This is the precept by which I have lived: Prepare for the worst; expect the best; and take what comes.” – Hannah Arendt

  108. “The best and most beautiful things in the world cannot be seen or even touched – they must be felt with the heart.” – Helen Keller

  109. “He who is brave is free.” – Lucius Annaeus Seneca
  110. “When something is important enough, you do it even if the odds are not in your favor.” – Elon Musk

  111. “I choose a block of marble and chop off whatever I don’t need.” – Auguste Rodin

  112. “Hope is the only bee that makes honey without flowers.” – Robert Green Ingersoll

  113. “He who knows that enough is enough will always have enough.” – Lao Tzu

  114. “Plans to protect air and water, wilderness and wildlife are in fact plans to protect man.” – Stewart Udall
  115. “In order to carry a positive action we must develop here a positive vision.” – Dalai Lama

  116. “A hero is someone who understands the responsibility that comes with his freedom.” – Bob Dylan
  117. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  118. “If we give something positive to others, it will return to us. If we give negative, that negativity will be returned.” – Allu Arjun
  119. “A good plan violently executed now is better than a perfect plan executed next week.” ~ George S. Patton
  120. “You must do the things you think you cannot do.”- Eleanor Roosevelt
  121. “Success is dependent on effort.” – Sophocles
  122. “Nobody who ever gave his best regretted it.” – George Halas
  123. “Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
  124. “And when I breathed, my breath was lightning.” – Black Elk
  125. “Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
  126. “You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
  127. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  128. “We are an impossibility in an impossible universe.” – Ray Bradbury
  129. “If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
  130. “I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
  131. Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
  132. “It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
  133. “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
  134. Surprise is the greatest gift which life can grant us.” –  Boris Pasternak
  135. “Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran 
  136. “Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
  137. “All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
  138. “There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” –  Colin Powell
  139. “There is more to life than increasing its speed.” – Mahatma Gandhi
  140. “Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
  141. “Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
  142. “Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
  143. “In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
  144. “Life is too short for long-term grudges.” – Elon Musk
  145. There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
  146. “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
  147. “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
  148. “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
  149. “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
  150. “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
  151. “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
  152. “Let there be work, bread, water and salt for all.” – Nelson Mandela
  153. “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
  154. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  155. “I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
  156. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  157. “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
  158. “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
  159. “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
  160. “Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
  161. “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
  162. “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
  163. “Delete the negative; accentuate the positive!” – Donna Karan
  164. “It’s crazy how fast time flies and how things progress.” – Nathan Chen
  165. “The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
  166. “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
  167. “Everything has beauty, but not everyone sees it.” – Confucius
  168. A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
  169. “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
  170. “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
  171. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  172. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  173. “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
  174. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  175. “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
  176. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  177. “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
  178. “No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
  179. “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
  180. “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
  181. “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
  182. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  183. “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
  184. “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
  185. “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
  186. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  187. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  188. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  189. “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
  190. “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
  191. “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese 
  192. “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
  193. “Never do anything against conscience even if the state demands it.”– Albert Einstein
  194. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  195. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  196. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  197. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  198. “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
  199. “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
  200. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
  201. “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
  202. “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch 
  203. “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
  204. “The secret of getting ahead is getting started.” – Mark Twain
  205. “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe


Post View Count : 501